Mar 1, 2022 | Technology News
The EMA has recommended granting European Commission (EC) approval to Novartis’ CAR T-cell therapy, Kymriah® (tisagenlecleucel), to treat adult relapsed or refractory (r/r) follicular lymphoma (FL) patients. In April 2020, the US Food and Drug Administration granted...
Mar 1, 2022 | Technology News
Researcher reported in Nature in March 2022, that the first two patients who received an infusion of autologous CAR T-cells in 2010 when they were no longer responsive to chemotherapy, remain in remission. Their CAR T-cell population are still proliferating in their...
